news-details
Watchlist

6 Stocks Trending with 50% Potential Upside

Powered by marketinsiderspress.com

According to marketinsiderspress.com, here is a list of 6 several stocks that appear to be trending by receiving buy ratings from top Wall Street analysts and showing positive investor sentiment, as well as news headlines. Based on the analyst's price targets, all of these names have over 50% potential upside. With that said, our editors here at marketinsiderspress.com, are adding them to our watchlist to see if this momentum continues.

 Planet Labs PBC, PL
Summary: Planet Labs Inc. is a provider of global, daily satellite imagery and geospatial solutions. It offer mission-critical data, advanced insights, and software solutions principally to agriculture, forestry, intelligence, education and finance companies. Planet Labs Inc., formerly known as dMY Technology Group Inc. IV, is based in SAN FRANCISCO.
Jeff Van analyst at Craig-Hallum reiterates coverage on Planet Labs PBC (PL) in the Technology sector with a Buy rating and has set a price target of $ 10.

TipRanks.com reports that Planet Labs PBC currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $9.67. 

In addition, TradingView issued a Sell rating for PL over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PL.

For the complete breakdown on PL, please click here >>

 Cytokinetics, CYTK
Summary: Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Serge Belanger analyst at Needham reiterates coverage on Cytokinetics (CYTK) in the Healthcare sector with a Buy rating and has set a price target of $ 60.

TipRanks.com reports that Cytokinetics currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $63.82. 

In addition, TradingView issued a Buy rating for CYTK over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYTK.

For the complete breakdown on CYTK, please click here >>

 BRP, DOOO
Summary: BRP Inc. designs, develops, manufactures and distributes recreational vehicles. The Company offers watercrafts, sport boats, snowmobiles, pontoons, marine propulsion systems and all-terrain and utility vehicles, as well as engines for karts, motorcycles and recreational aircrafts. BRP Inc. is headquartered in Valcourt, Canada.
Martin Landry analyst at Stifel Nicolaus reiterates coverage on BRP (DOOO) in the Consumer Goods sector with a Buy rating and has set a price target of $ 111.24.

TipRanks.com reports that BRP currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $102.75. 

In addition, TradingView issued a Sell rating for DOOO over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on DOOO.

For the complete breakdown on DOOO, please click here >>

 AZEK Company, AZEK
Summary: The AZEK Company Inc. is manufacturer of residential and commercial building products. The AZEK Company Inc. is based in CHICAGO.
Anthony Pettinari analyst at Citigroup reiterates coverage on AZEK Company (AZEK) in the Industrial Goods sector with a Buy rating and has set a price target of $ 23.

TipRanks.com reports that AZEK Company currently has 17 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $27.33. 

In addition, TradingView issued a Sell rating for AZEK over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AZEK.

For the complete breakdown on AZEK, please click here >>

 Olin, OLN
Summary: Olin Corporation is a vertically-integrated global producer and distributor of chemical products and U.S. maker of ammunition. Internationally, the company operates in regions including Latin America, Asia Pacific and Europe. Olin's operations are focused in three business segments: Chlor Alkali Products and Vinyls, Epoxy and Winchester. Chlor Alkali Products and Vinyls segment produces and sells chlorine and caustic soda, vinyl chloride monomer and ethylene dichloride, methylene chloride, methyl chloride, carbon tetrachloride, chloroform, trichloroethylene, perchloroethylene, hydrochloric acid, vinylidene chloride, hydrogen, potassium hydroxide and bleach products. The division is one of the largest marketers of caustic soda in Brazil. The company's diversified caustic soda sourcing enables it to supply global customers cost effectively.
Eric Petrie analyst at Citigroup reiterates coverage on Olin (OLN) in the Basic Materials sector with a Hold rating and has set a price target of $ 55.

TipRanks.com reports that Olin currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $75.55. 

In addition, TradingView issued a Sell rating for OLN over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OLN.

For the complete breakdown on OLN, please click here >>

 Bombardier, BDRBD
Summary: N/A
Kevin Chiang analyst at CIBC reiterates coverage on Bombardier (BDRBD) in the Technology sector with a Hold rating and has set a price target of $ 27.62.

TipRanks.com reports that Bombardier currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $42.11. 

In addition, TradingView issued a Sell rating for BDRBD over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BDRBD.

For the complete breakdown on BDRBD, please click here >>



FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more.

One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================